摘要
背景:近年来,许多研究都致力于生物标志物在心力衰竭领域的应用。 目的:研究microRNAs转录后在心力衰竭诊断和治疗中的调控作用。 方法:文献检索集中在microRNAs在心力衰竭中的作用。 结果:microRNAs在心衰病理表现过程中表达和调控。这一广泛而未知的遗传印记领域由小的非编码RNA分子组成,在特定条件或压力下,这些基因印记会被上调,并从器官释放到血液中。使用基于基因的策略治疗心衰在生物医学领域引起了极大的兴趣,因为它们可以作为生物标志物,提供有关心脏状态和功能的信息。由于它们能够在不改变基因序列的情况下诱导细胞水平的变化,因此它们似乎也是具有治疗潜力的有前途的工具。此外,随着microRNAs鉴定技术的基因组测序、量化和合成技术的进步,以及对microRNAs生物学及其在HF中的作用的研究进展,microRNAs有望用于HF患者并对其预后产生良好的影响。 结论:MicroRNAs参与了心力衰竭进展的多生物学过程的调控。需要更多的研究来实现microRNAs在心衰治疗中的临床应用价值。
关键词: 心脏纤维化,心肌细胞,心脏重塑,炎症,细胞治疗,再生。
Current Medicinal Chemistry
Title:MicroRNAs in the Management of Heart Failure
Volume: 28 Issue: 24
关键词: 心脏纤维化,心肌细胞,心脏重塑,炎症,细胞治疗,再生。
摘要:
Background: In recent years much research has been devoted to the deployment of biomarkers in the field of heart failure.
Objectives: To study the potential of post-transcriptional regulation by microRNAs on the diagnosis, management and therapy of heart failure.
Methods: Literature search focuses on the role of microRNAs in heart failure.
Results: MicroRNAs are expressed and regulated in the course of the pathological manifestations of heart failure (HF). This wide and uncharted area of genetic imprints consisting of small non-coding RNA molecule is upregulated and released into the bloodstream from organs under certain conditions and or stress. The use of genetically based strategies for the management of HF has gained great interest in the field of biomedical science because they can be used as biomarkers providing information regarding cardiac status and function. They also appear as promising tools with therapeutic potential because of their ability to induce changes at the cellular level without creating alterations in the gene sequence. In addition, with the advances in genomic sequencing, quantification and synthesis in technologies of microRNAs identification as well as the growing knowledge of the biology of miRNAs and their involvement in HF, it is expected to favorably affect the prognosis of HF patients.
Conclusion: MicroRNAs are involved in the regulation of multibiological processes involved in the progress of heart failure. More studies are needed to achieve a clinical valuable implementation of microRNAs in the management of HF.
Export Options
About this article
Cite this article as:
MicroRNAs in the Management of Heart Failure, Current Medicinal Chemistry 2021; 28 (24) . https://dx.doi.org/10.2174/0929867328666210218181441
DOI https://dx.doi.org/10.2174/0929867328666210218181441 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial
Current Hypertension Reviews The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Targeting Antioxidants to Mitochondria: A Potential New Therapeutic Strategy for Cardiovascular Diseases
Current Pharmaceutical Design Vitamin D Metabolism and Potential Effects of Vitamin D Receptor Modulation in Chronic Kidney Disease
Current Drug Metabolism The Fundamental Role of Stress Echo in Evaluating Coronary Artery Disease in Specific Patient Populations
Current Vascular Pharmacology Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results
Current Medicinal Chemistry Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Antioxidant Agents in Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Mechanisms of Cardiovascular Changes in an Experimental Model of Syndrome X and Pharmacological Intervention on the Renin-Angiotensin- System
Current Vascular Pharmacology Congestive Heart Failure and Thyroid Dysfunction: The Role of the Low T3 Syndrome and Therapeutic Aspects
Endocrine, Metabolic & Immune Disorders - Drug Targets NAD+, Sirtuins, and Cardiovascular Disease
Current Pharmaceutical Design Novel Oral Anticoagulants in the Treatment of Acute Coronary Syndromes: Is there any Room for New Anticoagulants?
Current Clinical Pharmacology Adult Neural Stem Cell Therapy: Expansion In Vitro, Tracking In Vivo and Clinical Transplantation
Current Drug Targets Sympathetic Overactivity in Hypertension and Cardiovascular Disease
Current Vascular Pharmacology Leptin Induces Neuroprotection Neurogenesis and Angiogenesis after Stroke
Current Neurovascular Research Catalytic Features, Regulation and Function of Myocardial Phospholipase A2
Current Medicinal Chemistry - Cardiovascular & Hematological Agents New Pharmacologic Approaches to Prevent Thromboembolism in Patients with Atrial Fibrillation
Current Vascular Pharmacology